Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trizivir vs Combivir plus Ziagen in HIV-1 Infection
NCT00004981Phase 3Unknown
- Sponsor
- GSK
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abacavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by GSK. Primary endpoint: Proportion of patients with HIV-1 RNA < 400 copies/mL or < 0.5 log increase at 24 weeks. Status: unknown.
02
Drugs
abacavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00004981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004981.